Clinical Laserthermia Systems

The study is being conducted by Urological Research Network, LLC, a Florida-based, not-for-profit clinical research organization. The study utilizes CLS’s TRANBERG® Thermal Therapy System in combination with the Focalyx® Fusion medical device for treatment organization, planning, image fusion, and real-time image guidance during the high-precision, focal laser ablation (FLA) treatment.

”The TRANBERG laser system provides a higher degree of precision and control over the ablation shape, size, and margin than cryotherapy or other focal therapies I’ve worked with and seen,” stated Dr. Fernando J. Bianco, principal investigator, Urological Research Network, LLC.  ”Additionally, I found the TRANBERG laser system to be very easy and intuitive to operate in conjunction with the Focalyx Fusion real-time, image guidance and treatment planning system.”

“We are very happy with how the Phase I clinical study was performed  in the US and the positive preliminary results. This is yet another milestone for CLS in the US market. We now hope to treat even more patients with our focal laser ablation technique with less discomfort, enabling fast recovery times, and significantly reducing the risk of unwanted side effects,” says Dan J. Mogren, CEO of Clinical Laserthermia Systems AB.

The information was submitted for publication, through the agency of the contact person set out below on 31 January 2023.

For more information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0)705 90 11 40
E-mail: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products  are  marketed  for  image-guided  laser  ablation  and  used in studies for  treatment  with  imILT®,  

the  Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.

For more information about CLS, please visit the Company's website: clinicallaser.se